PHARMACEUTICAL 2013

Alnylam Pharmaceuticals INC
Rank 115 of 218



PHARMACEUTICAL 2013

Alnylam Pharmaceuticals INC
Rank 115 of 218

The relative strengths and weaknesses of Alnylam Pharmaceuticals INC are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Alnylam Pharmaceuticals INC compared to the market average is the variable Other Assets, increasing the Economic Capital Ratio by 82% points.The greatest weakness of Alnylam Pharmaceuticals INC is the variable Other Liabilities, reducing the Economic Capital Ratio by 73% points.

The company's Economic Capital Ratio, given in the ranking table, is 221%, being 0.53% points above the market average of 220%.

Input Variable	Value in 1000 USD
Assets, Current	125,456
Cost of Goods Sold	0
Intangible Assets	0
Liabilities, Current	48,345
Liabilities, Non-Current	0
Other Assets	142,265
Other Compr. Net Income	15,827
Other Expenses	54,428
Other Liabilities	105,122
Other Net Income	79,595
Other Revenues	0
Property and Equipment	19,799
Research and Development	86,569
Selling, General and Administrative Expense	44,612

Output Variable	Value in 1000 USD
Assets	287,520
Liabilities	153,467
Expenses	185,609
Revenues	0
Stockholders Equity	134,053
Net Income	-106,014
Comprehensive Net Income	-98,100
BaseVar	361,009
ECR before LimitedLiability	88%
Economic Capital Ratio	221%